Batch records from multi-kilogram GMP campaigns consistently document that the integrity of the (2S,4R)-4-hydroxypyrrolidine chiral center in O1-tert-butyl O2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate is preserved only when the methyl ester is kept intact during early-stage amide bond formation, a constraint that defines the entire synthetic route to the macrocyclic HCV NS3/4A protease inhibitor glecaprevir. In the coupling of this pyrrolidine derivative with (1R,2R)-1-amino-2-phenylcyclopropanecarboxylic acid ethyl ester, the ester is charged in a slight molar excess of 1.08–1.15 eq relative to the amine component, using HATU as the activating agent and N-methylmorpholine as base in anhydrous dichloromethane at −5 °C to 0 °C. Deviation beyond 1.20 eq leads to bis-acylation impurities that co-elute with the product on normal-phase silica, forcing a costly second chromatographic separation. The subsequent steps—Boc-deprotection with HCl in isopropanol at ≤25 °C, macrocyclization via Pd-catalyzed intramolecular C–N coupling under rigorously oxygen-free conditions in a Hastelloy C-22 vessel, and final global deprotection—are telescoped into a single solvent front (toluene/acetonitrile) to comply with ICH Q3C residual solvent limits, specifically Class 2 solvents toluene (≤890 ppm) and acetonitrile (≤410 ppm). The terminal drug substance glecaprevir, co-formulated with pibrentasvir as the fixed-dose combination Mavyret™, must meet the specification of ≥99.0 area% purity by HPLC (USP <621>) with no single unknown impurity exceeding 0.10%, and the chiral purity is validated at ≥99.5% ee by chiral stationary-phase HPLC against a racemic reference. Process engineers at multiple contract manufacturing organisations have reported that batch failures most frequently originate from inadequate control of water content in the coupling step—Karl Fischer titration of the dichloromethane must show ≤0.03% w/w H₂O—otherwise the HATU-active ester hydrolyses before aminolysis, dragging the yield below the economic threshold of 78% isolated yield.
A Macrocyclic NS3/4A Inhibitor Scaffold Requiring a (2S,4R) Configuration at P2
When the 15-membered macrocyclic core of voxilaprevir is assembled, the (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate ester is temporarily transformed into the corresponding hydroxy acid through selective hydrolysis of the methyl ester, a transformation that demands precise stoichiometric control to prevent epimerisation at the C2 position. Lithium hydroxide monohydrate is employed at 1.02–1.05 eq in a tetrahydrofuran/water (3:1 v/v) mixture at 0–5 °C; exceeding 1.10 eq or allowing the internal temperature to rise above 10 °C generates the (2R) diastereomer at levels above 0.5%, which cannot be purged in the downstream crystallisation of the dicyclohexylamine salt. The resulting hydroxy acid is then activated with 2,4,6-trichlorobenzoyl chloride (Yamaguchi reagent) and slowly added over 6–8 hours to a refluxing toluene solution to effect the intramolecular macrolactonisation, a step that requires real-time in-process control by FTIR to track the disappearance of the mixed anhydride band at 1815 cm⁻¹. The regulatory dossier filed under US DMF Type II mandates compliance with ICH M7 for mutagenic impurities, specifically the control of mesityl oxide derived from the acetone used during Boc deprotection, with a purge factor calculated to ensure a theoretical intake below the threshold of toxicological concern (1.5 µg/day). The finished voxilaprevir, after salt formation with tromethamine, is compressed into the triple-combination tablet Vosevi™ together with sofosbuvir and velpatasvir; each tablet is tested per Ph. Eur. 2.9.3 for dissolution in 900 mL of pH 6.8 phosphate buffer with 0.2% cetyltrimethylammonium bromide at 37 °C, paddle speed 75 rpm, Q-value ≥80% at 30 min.
In the domain of asymmetric organocatalysis, O1-tert-butyl O2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate functions as the starting point for preparing (2S,4R)-4-(tert-butyldimethylsilyloxy)pyrrolidine-2-carboxylate derivatives that, after Grignard addition, yield the privileged diarylprolinol silyl ether catalyst class. Conversion of the free hydroxyl to the silyl ether is executed with tert-butyldimethylsilyl chloride (1.10–1.25 eq) and imidazole (2.5 eq) in dimethylformamide at 20–25 °C under nitrogen; incomplete silylation leaves residual starting material that co-crystallises with the next intermediate, degrading the enantioselectivity of the final catalyst. The methyl ester is then subjected to addition of 3,5-bis(trifluoromethyl)phenylmagnesium bromide (freshly titrated, 3.0–3.3 eq) in tetrahydrofuran at −15 °C to generate the tertiary alcohol, with strict exclusion of moisture (KF ≤50 ppm in THF) because adventitious water quenches the Grignard reagent and leads to variable catalyst loading in the target asymmetric aldol reaction. When this catalyst is applied to the cross-aldol of 4-nitrobenzaldehyde and acetone, a loading of 5 mol% at 0 °C for 18 h delivers the R-configured β-hydroxy ketone in 94–97% ee as verified by chiral SFC analysis; the enantiomeric excess is determined against a racemic sample prepared with DL-proline under otherwise identical conditions, per ICH Q2(R1) validated method with LOD 0.05% and LOQ 0.15%. The downstream utility spans intermediates for chiral chromane antihypertensives and perfume-grade methyl jasmonate analogues, where residual palladium from alternative transition-metal catalysis must be held below 10 ppm (USP <232>) to avoid off-odour and comply with IFRA standards for fragrance materials.
Can This Chiral Pyrrolidine Ester Serve as a Gateway to Conformation-Locked Proline Mimetics for PET Imaging?
Fluorine-18 radiolabelling of (2S,4R)-4-fluoro-L-proline, a non-natural amino acid that resists metabolic degradation and accumulates in collagen-rich fibrotic tissue, depends on the clean activation of the secondary hydroxyl in O1-tert-butyl O2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate. On a GE TRACERlab FXFN automated synthesis module, the methyl ester is first reacted with Deoxo-Fluor® (bis(2-methoxyethyl)aminosulfur trifluoride, 1.2–1.4 eq) in dichloromethane at −20 °C for 15 min to effect deoxyfluorination with retention of configuration; the crude 4-fluoroproline methyl ester is purified in-line by SPE (silica cartridge conditioned with heptane) before quantitative acidolysis with trifluoroacetic acid/triisopropylsilane (95:5 v/v) removes both Boc and methyl ester groups. The resulting (2S,4R)-4-fluoro-L-proline is formulated as a lyophilised precursor in citrate buffer pH 4.0, ready for 18F-fluoride incorporation via isotopic exchange under radiopharmaceutical cleanroom ISO Class 5 conditions. The final 18F-product must meet the Ph. Eur. monograph 01/2023:2798 specification for radiochemical purity ≥95% by radio-TLC, residual Deoxo-Fluor® derived sulfite ≤50 µg/Vmax, and endotoxin ≤1.75 EU/mL (Ph. Eur. 2.6.14). At the clinical CMO site, each batch is accompanied by a 3D chiral chromatogram (Chiralpak QD-AX, 150×4.6 mm, ammonium formate buffer pH 3.8/acetonitrile 40:60) demonstrating baseline separation of the (2S,4S) diastereomer (relative retention 1.23) and the (2R) enantiomers, because even 2% of the opposite enantiomer shifts the PET signal from fibrotic to non-specific background in the rodent bleomycin-lung-fibrosis model. The finished drug product, formulated as an isotonic sterile solution of 18F-fluoroproline in 10 mL saline, is released for use in investigational PET/CT imaging of idiopathic pulmonary fibrosis and cirrhotic liver stroma under an active IND with a shelf-life of 8 hours from end of synthesis, constrained by the 109.8 min half-life of F-18 and the European Pharmacopoeia limits for radiochemical purity decay.
